Response to Rituximab after Failure of Cyclophosphamide in the Induction Treatment in a Patient with cANCA-associated Vasculitis and Pachymeningitis: a Case Report

Psenak, O; Greil, R; Modern Rheumatology. 2021; 15(4): 68-71.

Anti-coagulation for COVID-19 treatment: both anti-thrombotic and anti-inflammatory?

Paar, V; Wernly, B; Zhou, Z; Motloch, LJ; Hoppe, UC; Egle, A; Lichtenauer, M; J Thromb Thrombolysis. 2021; 51(1):226-231

Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients

Schlick, K; Hohla, F; Hamacher, F; Hackl, H; Hufnagl, C; Markus, S; Magnes, T; Gampenrieder, SP; Melchardt, T; Stattner, S; Hauser-Kronberger, C; Greil, R; Rinnerthaler, G FUTUR SCI OA. 2021; 7(2): FSO644

Olaratumab plus anthracyline in advanced/metastatic soft tissue sarcoma : Data of real-world utilization in Austria.

Seeber, A; Weiss, L; Romeder, F; Szkandera, J; Kuehr, T; Kostner, S; Pichler, P; Jaeger, T; Kocher, F; Greil, R; Brodowicz, T Wien Klin Wochenschr. 2021; 133(1-2):21-25

Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14).

Gillessen, S; Plütschow, A; Fuchs, M; Markova, J; Greil, R; Topp, MS; Meissner, J; Zijlstra, JM; Eichenauer, DA; Bröckelmann, PJ; Diehl, V; Borchmann, P; Engert, A; von Tresckow, B; Lancet Haematol. 2021; 8(4): e27-e288.

Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor.

Staber, PB; Jurczak, W; Greil, R; Vucinic, V; Middeke, JM; Montillo, M; Munir, T; Neumeister, P; Schetelig, J; Stilgenbauer, S; Striebel, F; Dirnberger-Hertweck, M; Weirather, J; Brugger, W; Kelemen, P; Wendtner, CM; Woyach, JA; Leuk Lymphoma. 2021; 62(14): 3440-3451.

PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial.

Kreissl, S; Goergen, H; Buehnen, I; Kobe, C; Moccia, A; Greil, R; Eichenauer, DA; Zijlstr, JM; Markova, J; Meissner, J; Feuring-Buske, M; Soekler, M; Beck, HJ; Willenbacher, W; Ludwig, WD; Pabst, T; Topp, MS; Hitz, F; Bentz, M; Keller, UB; Kuhnhardt, D; Ostermann, H; Hertenstein, B; Ulitzky, WA; Maschmeyer, G; Vieler, T; Eich, H; Baues, C; Stein, H; Fuchs, M; Diehl, V; Dietlein, M; Engert, A; Borchmann, P LANCET HAEMATOL. 2021; 8(6): e398-e409.

Influence of Height on Risk and Outcome of Patients with Early Breast Cancer: A Pooled Analysis of 4,925 Patients from 5 Randomized Trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG)

Gampenrieder, SP; Pircher, M; Fesl, C; Rinnerthaler, G; Mlineritsch, B; Greil-Ressler, S; Steger, GG; Sagaster, V; Fitzal, F; Exner, R; Devyatko, Y; Balic, M; Stoger, H; Suppan, C; Bauernhofer, T; Singer, CF; Pfeiler, G; Seifert, M; Helfgott, R; Heck, D; Rumpold, H; Kwasny, W; Wieder, U; Gnant, M; Greil, R BREAST CARE. 2021;

Endothelin-1 genetic polymorphism (SNP rs5370-TT) fails to predict resistance to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial

Gampenrieder, SP; Steiner, M; Hufnagl, C; Hackl, H; Rinnerthaler, G; Westphal, T; Huemer, F; Monzo-Fuentes, C; Morre, P; Hauser-Kronberger, C; Greil, R ANN ONCOL. 2022; 33: S141-S141.

Phase 1/2a trial of nadunolimab, a first-in-class fully humanized monoclonal antibody against IL1RAP, in combination with gemcitabine and nab-paclitaxel (GN) in patients with pancreatic adenocarcinoma (PDAC).

Van Cutsem, E; Eefsen, RL; Ochsenreither, S; Zvirbule, Z; Ivanauskas, A; Arnold, D; Baltruskeviciene, E; Pfeiffer, P; Yachnin, J; Garcia Carbonero, R; Greil, R; Jungels, C; Poulsen, L; Awada, A; Garcia Ribas, I; Losic, N; Collignon, J J CLIN ONCOL. 2022; 40(16):